Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
besilesomab
CIS bio international
V09HA03
besilesomab
Diagnostic radiopharmaceuticals
Osteomyelitis; Radionuclide Imaging
This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection.
Revision: 6
Authorised
2010-01-11
24 B. PACKAGE LEAFLET 25 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT SCINTIMUN 1 MG KIT FOR RADIOPHARMACEUTICAL PREPARATION besilesomab READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or the nuclear medicine specialist who will supervise the procedure. - If you get any side effects, talk to your nuclear medicine doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Scintimun is and what it is used for 2. What you need to know before you are given Scintimun 3. How Scintimun is given 4. Possible side effects 5. How Scintimun is stored 6. Contents of the pack and other information 1. WHAT SCINTIMUN IS AND WHAT IT IS USED FOR Scintimun is a medicine containing an antibody (besilesomab) used to target specific cells called granulocytes (a type of white blood cells involved in the inflammation process) in your body. Scintimun is used for the preparation of a radioactive solution for injection of technetium( 99m Tc)- besilesomab. Technetium( 99m Tc) is a radioactive element allowing the organs where besilesomab accumulates to be seen using a special camera. This medicine is a radiopharmaceutical product for diagnostic use only in adults. After injection into your vein, your doctor can obtain pictures (scans) of your organs that give more information about the detection of sites of inflammation and/or infection. However Scintimun should not be used for the diagnosis of diabetic foot infection. The use of Scintimun does involve exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweights the risk due to radiation. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN SCINTIMUN _ _ SCINTIMUN MUST NOT BE USED: - if you are aller Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Scintimun 1 mg kit for radiopharmaceutical preparation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of Scintimun contains 1 mg of besilesomab. Besilesomab is an anti-granulocyte monoclonal antibody (BW 250/183), produced in murine cells. The radionuclide is not part of the kit. Excipient(s) with known effect Each vial of Scintimun contains 2 mg of sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Kit for radiopharmaceutical preparation. Scintimun: white powder Solvent for Scintimun: white powder 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This medicinal product is for diagnostic use only. After radiolabelling with sodium pertechnetate ( 99m Tc) solution, the technetium ( 99m Tc) besilesomab solution obtained is indicated in adults for scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION This medicinal product is for use in designated nuclear medicine facilities only, and should only be handled by authorised personnel. Posology _Adults _ The recommended activity of technetium ( 99m Tc) besilesomab should be between 400 MBq and 800 MBq. This corresponds to the administration of 0.25 to 1 mg of besilesomab. For repeated use, see section 4.4. _Elderly _ No dose adjustment is required. 3 _Renal impairment / Hepatic impairment _ Formal studies have not been performed in patients with renal or hepatic impairment. However, due to the nature of the molecule and the short half-life of technetium ( 99m Tc) besilesomab, dose adjustment is not necessary in such patients. _Paediatric population _ The safety and efficacy of Scintimun in children and adolescents have not yet been established. No data are available. Method of administration The rad Lue koko asiakirja